Blog Post

MDA logo
Blog Post

Catalyst Pharmaceuticals Announces Positive Results from Phase 2b Trial of Firdapse in Patients with Muscle-Specific Kinase Antibody Positive Myasthenia Gravis (MuSK-MG)

By Jeanene Swanson | January 30, 2019
Blog Post

Planned Giving: A Different Kind of Donation

By Lindsey Baker | January 30, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Brainstorm Cell Therapeutics Seeks Participants for a Phase 3 ALS Study

By MDA Staff | January 16, 2019
MDA logo
Blog Post

FDA Awards Fast Track Status to RNS60, Revalesio’s Investigational Therapy for ALS

By Jeanene Swanson | January 16, 2019
Blog Post

MDA Awards Venture Philanthropy Grant to AcuraStem to Develop Treatment for ALS

By Jeanene Swanson | January 15, 2019
Blog Post

Newborn Screening for DMD and BMD: MDA Needs Your Help

By MDA Staff | January 15, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Orphazyme Seeks Participants for a Phase 3 ALS Study

By MDA Staff | January 11, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Catabasis Seeks Participants for a Phase 3 DMD Study

By MDA Staff | January 10, 2019
Blog Post

Wave Life Sciences Announces Phase 2/3 Duchenne Muscular Dystrophy Clinical Trial of Suvodirsen (WVE-210201) Selected for FDA Complex Innovative Trial Designs Pilot Program

By Jeanene Swanson | January 8, 2019
Blog Post

FDA Grants Orphan Drug Designation to Myonexus Therapeutics’ MYO-102 Gene Therapy Drug for Limb-Girdle Muscular Dystrophy Type 2D

By Jeanene Swanson | January 4, 2019